{"id":170171,"date":"2025-08-14T04:43:40","date_gmt":"2025-08-14T08:43:40","guid":{"rendered":"https:\/\/44.250.171.167\/?p=170171"},"modified":"2025-08-14T08:37:11","modified_gmt":"2025-08-14T12:37:11","slug":"divis-laboratories-q1-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/divis-laboratories-q1-fy26-earnings-results\/","title":{"rendered":"Divi&#8217;s Laboratories Q1 FY26 Earnings Results"},"content":{"rendered":"<p>Divi\u2019s Laboratories Limited, incorporated in 1990, is engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. Presenting below are its <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/40be5eb6-1025-4aa1-a014-c7502ef48e18.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> Earnings Results.<\/p>\n<h2><strong>Q1 FY26 Earnings Results<\/strong><\/h2>\n<ul>\n<li><strong>Revenue:<\/strong> \u20b92,410 crore, up 13.79% year-on-year (YoY) from \u20b92,118 crore in Q1 FY25.<\/li>\n<li><strong>Total Expenses:<\/strong> \u20b91,796 crore, up 12.74% YoY from \u20b91,593 crore.<\/li>\n<li><strong>Consolidated Net Profit (PAT):<\/strong> \u20b9545 crore, up 26.74% from \u20b9430 crore in the same quarter last year.<\/li>\n<li><strong>Earnings Per Share (EPS):<\/strong> \u20b920.53, up 26.73% from \u20b916.20 YoY.<\/li>\n<\/ul>\n<h2><strong>Operational &amp; Strategic Update<\/strong><\/h2>\n<ul>\n<li><strong>Healthy Revenue Growth:<\/strong> The near 14% YoY growth in revenues was supported by sustained demand in key export markets, a robust order book for APIs and intermediates, and increased traction in nutraceuticals.<\/li>\n<li><strong>Disciplined Cost Management:<\/strong> Total expenses rose at a slightly slower pace than revenues, indicating operational efficiencies and effective input cost control.<\/li>\n<li><strong><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/40be5eb6-1025-4aa1-a014-c7502ef48e18.pdf\" target=\"_blank\" rel=\"noopener\">Strong Profitability Expansion<\/a><\/strong><strong>:<\/strong> Net profit and EPS grew by nearly 27%, driven by margin improvement on the back of better product mix, operational leverage, and favorable currency movement.<\/li>\n<li><strong>Global Market Presence:<\/strong> With a diversified customer base across regulated markets such as the US, Europe, and Japan, Divi\u2019s continues to leverage its long-standing relationships and compliance record to secure repeat and long-term business.<\/li>\n<li><strong>R&amp;D and Capacity Expansion:<\/strong> Continued investments in research, technology upgrades, and manufacturing capacity are enhancing the company\u2019s competitive positioning in high-value API segments.<\/li>\n<\/ul>\n<h2><strong>Corporate Developments in Q1 FY26 Earnings<\/strong><\/h2>\n<p><a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/40be5eb6-1025-4aa1-a014-c7502ef48e18.pdf\" target=\"_blank\" rel=\"noopener\">Q1 FY26<\/a> results reinforce Divi\u2019s Laboratories\u2019 ability to deliver strong earnings growth supported by demand resilience, operational excellence, and product portfolio diversification. The company\u2019s leadership in API manufacturing positions it well to capture growth opportunities in regulated and emerging markets.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-170172\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png\" alt=\"DIVISLAB Q1 FY26 Earnings Results\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n<h2><strong>Looking Ahead<\/strong><\/h2>\n<p>Divi\u2019s Laboratories Ltd aims to build on its global leadership in APIs through ongoing capacity expansion, scaling of nutraceuticals, and entry into complex molecules. Focused execution in R&amp;D, quality compliance, and cost optimization is expected to sustain growth momentum and enhance long-term shareholder value through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts,<a href=\"https:\/\/44.250.171.167\/symbol\/divislab\/\"> click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Divi\u2019s Laboratories Limited, incorporated in 1990, is engaged in the manufacture and export of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. Presenting below are its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b92,410 crore, up 13.79% year-on-year (YoY) from \u20b92,118 crore in Q1 FY25. Total Expenses: \u20b91,796 crore, up 12.74% YoY from [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":170172,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10162],"class_list":["post-170171","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/DILAB.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170965,"url":"https:\/\/alphastreet.com\/india\/caplin-point-q1-fy26-earnings-results\/","url_meta":{"origin":170171,"position":0},"title":"Caplin Point Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 5, 2025","format":false,"excerpt":"Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of active pharmaceutical ingredients APIs, finished formulations, research and development, and clinical research. The company has a strong international footprint with significant presence in Latin America, Africa, the USA, and other key markets. Q1 FY26 Earnings Summary Revenue: \u20b9510\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CAPLIPOINT Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CAPLI.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170341,"url":"https:\/\/alphastreet.com\/india\/unichem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170171,"position":1},"title":"Unichem Laboratories Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 19, 2025","format":false,"excerpt":"Unichem Laboratories Ltd is involved in pharmaceuticals in Generics, APIs and Contract Manufacturing (CMO) areas. The company operates 3 formulation facilities at Goa, Baddi, and Ghaziabad, and 3 API facilities at Roha, Pithampur, and Kolhapur. The company has initiated backward integration and upscaling for 6-8 major captive APIs. At the\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Unichem Laboratories Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/7-7.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":169930,"url":"https:\/\/alphastreet.com\/india\/alembic-pharmaceuticals-q1-fy26-earnings-results-revenue-up-10-net-profit-rises-14-yoy\/","url_meta":{"origin":170171,"position":2},"title":"Alembic Pharmaceuticals Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 8, 2025","format":false,"excerpt":"Alembic Pharmaceuticals Limited is a leading player in the pharmaceutical industry, engaged in the development, manufacturing, and marketing of formulations and active pharmaceutical ingredients (APIs). The company operates 3 R&D centers and 5 advanced manufacturing facilities, supporting global exports and a robust domestic presence. Presenting below are its Q1 FY26\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"APLLTD Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/APL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170582,"url":"https:\/\/alphastreet.com\/india\/alkem-laboratories-q1-fy26-earnings-results\/","url_meta":{"origin":170171,"position":3},"title":"Alkem Laboratories Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 25, 2025","format":false,"excerpt":"Alkem Laboratories Ltd is a global pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results Revenue: \u20b93,371 crore, up 11.18% year-on-year (YoY) from \u20b93,032 crore in Q1 FY25. Total Expenses: \u20b92,750 crore, up 8.61%\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"ALKEM Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/ALKEM.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171740,"url":"https:\/\/alphastreet.com\/india\/rpg-life-sciences-q2-fy26-earnings-results\/","url_meta":{"origin":170171,"position":4},"title":"RPG Life Sciences Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"October 22, 2025","format":false,"excerpt":"Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients. Presenting below are its Q2 FY26 earnings results. \u00a0 Q2 FY26 Earnings Results Revenue from Operations:\u00a0\u20b9181.7 crore, up\u00a05.5% YoY\u00a0from \u20b9172.2 crore and\u00a07.6% QoQ\u00a0from \u20b9168.9 crore in Q1 FY26, driven by strong domestic\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"RPG Life Sciences Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/RPG-Life-Sciences-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":171070,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-q1-fy26-earnings-results\/","url_meta":{"origin":170171,"position":5},"title":"Concord Biotech Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 9, 2025","format":false,"excerpt":"Concord Biotech Limited, incorporated in 1984, is an India-based R&D-driven biopharma company specializing in the manufacture of fermentation-based active pharmaceutical ingredients (APIs) primarily for immunosuppressants and oncology. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results: Revenue: \u20b9204 crore, down 5.56% year-on-year YoY from \u20b9216 crore Total Expenses:\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CONCORDBIO Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=170171"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/170171\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/170172"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=170171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=170171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=170171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}